[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590238":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":31,"locations":37,"responsibleParty":265,"collaborators":26,"id":267,"slug":268,"hasResults":269,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":269,"sex":275,"minAge":276,"maxAge":277,"enrollmentInfo":278,"targetDuration":26,"studyType":281,"phases":282,"briefSummary":284,"conditions":285,"keywords":288,"overallStatus":148,"whyStopped":26,"lastUpdateSubmitDate":293,"lastUpdatePostDateStruct":294,"startDateStruct":297,"completionDateStruct":299,"leadSponsor":301,"locationsCount":302},{"fullName":5,"class":6},"Istituto Oncologico Veneto IRCCS","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Silbrain_Experimental Arm","EXPERIMENTAL","Concomitant radiotherapy (60 gy in 30 fractions) + temozolomide 75mg\u002Fmq + silibinin 2 sachets\u002Fday dissolved in water throughout concomitant treatment followed by temozolomide cp, 150 mg\u002Fm2-200mg\u002Fm2, g1-5 q28d + silibinin 2 sachets\u002Fday dissolved in water, day 1-28, q28d for 6cycles. Silibinin will be continued until disease progression or up to 24 months. In patients who develop progression during temozolomide treatment, administration of silibinin will be continued for up to 6 months after the last dose of temozolomide.",[13],"Dietary Supplement: Silibinin as STAT3 inhibitor",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo_Control Arm","PLACEBO_COMPARATOR","Concomitant radiotherapy (60 gy in 30 fractions) + temozolomide 75mg\u002Fmq + placebo 2 sachets\u002Fday dissolved in water throughout concomitant treatment followed by temozolomide cp, 150 mg\u002Fm2-200mg\u002Fm2, g1-5 q28d + placebo 2 sachets\u002Fday dissolved in water, day 1-28, q28d for 6 cycles. Silibinin\u002FPlacebo may be continued until disease progression at the discretion of the physician. Silibinin\u002FPlacebo will be continued until disease progression or up to 24 months. In patients who develop progression during temozolomide treatment, administration of silibinin (or placebo) will be continued for up to 6 months after the last dose of temozolomide.",[19],"Other: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DIETARY_SUPPLEMENT","Silibinin as STAT3 inhibitor","Sillbrain will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Each 3.7 g sachet of Sillbrain contains 500 mg silibinin. Every patient will assume 2 sachets\u002Fday for a total of 1 g\u002Fday of silibinin.",[9],null,{"type":6,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo","Placebo will be available as granulate in sachets of 3.7g and it will be administered twice a day during chemo-radiotherapy and day 1-28 in maintenance phase every cycle. Every patient will assume 2 sachets\u002Fday for a total of 1 g\u002Fday of placebo.",[15],[32],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},"Giuseppe Lombardi, MD","CONTACT","0498215888","giuseppe.lombardi@iov.veneto.it",[38,57,72,87,102,117,131,146,159,174,189,204,214,227,241,254],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"IRCCS Istituto delle Scienze Neurologiche di Bologna","NOT_YET_RECRUITING","Bologna","BO","40139","Italy","IT",{"type":47,"coordinates":48},"Point",[49,50],11.33875,44.49381,{"lat":50,"lon":49},[53],{"name":54,"role":34,"phone":55,"phoneExt":26,"email":56},"Enrico Franceschi, Prof","051 6225697","e.franceschi@isnb.it",{"facility":58,"status":40,"city":59,"state":60,"zip":61,"country":44,"countryCode":45,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"IRST Dino Amadori","Meldola","FC","47014",{"type":47,"coordinates":63},[64,65],12.0626,44.12775,{"lat":65,"lon":64},[68],{"name":69,"role":34,"phone":70,"phoneExt":26,"email":71},"Lorena Guerrieri, MD","0543739100","lorena.guerrieri@irst.emr.it",{"facility":73,"status":40,"city":74,"state":75,"zip":76,"country":44,"countryCode":45,"cosmosGeoPoint":77,"geoPoint":81,"contacts":82},"Azienda Ospedaliero Universitaria Policlinico \"G. Rodolico - San Marco \"","Catania","Italia\u002FCatania","95123",{"type":47,"coordinates":78},[79,80],15.07041,37.49223,{"lat":80,"lon":79},[83],{"name":84,"role":34,"phone":85,"phoneExt":26,"email":86},"Giuseppe Barbagallo, Prof","095 3781220","gbarbagallo@unict.it",{"facility":88,"status":40,"city":89,"state":90,"zip":91,"country":44,"countryCode":45,"cosmosGeoPoint":92,"geoPoint":96,"contacts":97},"Azienda Ospedaliera Universitaria - Careggi","Florence","Italia\u002FFI","50134",{"type":47,"coordinates":93},[94,95],11.24626,43.77925,{"lat":95,"lon":94},[98],{"name":99,"role":34,"phone":100,"phoneExt":26,"email":101},"Lorenzo Livi, Prof","055-7947264","lorenzo.livi@unifi.it",{"facility":103,"status":40,"city":104,"state":105,"zip":106,"country":44,"countryCode":45,"cosmosGeoPoint":107,"geoPoint":111,"contacts":112},"ARNAS G.Brotzu P.O Armando Businco","Cagliari","Italy\u002FCagliari","09047",{"type":47,"coordinates":108},[109,110],9.11917,39.23054,{"lat":110,"lon":109},[113],{"name":114,"role":34,"phone":115,"phoneExt":26,"email":116},"Massimo Ghiani, MD","3460158418","massimo.ghiani@aob.it",{"facility":118,"status":40,"city":119,"state":120,"zip":121,"country":44,"countryCode":45,"cosmosGeoPoint":122,"geoPoint":126,"contacts":127},"USL Nord Ovest Toscana - Livorno","Livorno","Italy\u002FLivorno","57124",{"type":47,"coordinates":123},[124,125],10.32615,43.54427,{"lat":125,"lon":124},[128],{"name":129,"role":34,"phone":26,"phoneExt":26,"email":130},"Luisa Di Stefano, MD","annaluisa.distefano@uslnordovest.toscana.it",{"facility":132,"status":40,"city":133,"state":134,"zip":135,"country":44,"countryCode":45,"cosmosGeoPoint":136,"geoPoint":140,"contacts":141},"Ospedale del Mare, ASL Napoli1 Centro","Naples","italy\u002FNapoli","80147",{"type":47,"coordinates":137},[138,139],14.26811,40.85216,{"lat":139,"lon":138},[142],{"name":143,"role":34,"phone":144,"phoneExt":26,"email":145},"Pasqualina Giordano, MD","3932306352","giopas@email.it",{"facility":147,"status":148,"city":149,"state":150,"zip":151,"country":44,"countryCode":45,"cosmosGeoPoint":152,"geoPoint":156,"contacts":157},"Istituto Oncologico Veneto","RECRUITING","Padova","Italy\u002FPadova","35128",{"type":47,"coordinates":153},[154,155],11.14261,44.38225,{"lat":155,"lon":154},[158],{"name":33,"role":34,"phone":35,"phoneExt":26,"email":36},{"facility":160,"status":40,"city":161,"state":162,"zip":163,"country":44,"countryCode":45,"cosmosGeoPoint":164,"geoPoint":168,"contacts":169},"Istituto Neurologico Nazionale a Carattere Scientifico IRCCS - Fondazione Mondino","Pavia","Italy\u002FPavia","27100",{"type":47,"coordinates":165},[166,167],9.15917,45.19205,{"lat":167,"lon":166},[170],{"name":171,"role":34,"phone":172,"phoneExt":26,"email":173},"Enrico Marchioni, MD","0382 1891643","enrico.marchioni@mondino.it",{"facility":175,"status":40,"city":176,"state":177,"zip":178,"country":44,"countryCode":45,"cosmosGeoPoint":179,"geoPoint":183,"contacts":184},"Azienda Ospedaliera Universitaria G.Martino","Messina","ME","98124",{"type":47,"coordinates":180},[181,182],15.55256,38.19394,{"lat":182,"lon":181},[185],{"name":186,"role":34,"phone":187,"phoneExt":26,"email":188},"Maria Caffo, Prof","3405126187","mcaffo@unime.it",{"facility":190,"status":40,"city":191,"state":192,"zip":193,"country":44,"countryCode":45,"cosmosGeoPoint":194,"geoPoint":198,"contacts":199},"Istituto Tumori Regina Elena IRCCS","Roma","RM","00128",{"type":47,"coordinates":195},[196,197],11.10642,44.99364,{"lat":197,"lon":196},[200],{"name":201,"role":34,"phone":202,"phoneExt":26,"email":203},"Veronica Villani, MD","065291103","veronica.villani@ifo.it",{"facility":205,"status":40,"city":191,"state":192,"zip":26,"country":44,"countryCode":45,"cosmosGeoPoint":206,"geoPoint":208,"contacts":209},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"type":47,"coordinates":207},[196,197],{"lat":197,"lon":196},[210],{"name":211,"role":34,"phone":212,"phoneExt":26,"email":213},"Silvia Chiesa, MD","3384357241","silvia.chiesa@policlinicogemelli.it",{"facility":215,"status":40,"city":216,"state":26,"zip":26,"country":44,"countryCode":45,"cosmosGeoPoint":217,"geoPoint":221,"contacts":222},"Policlinico San Martino - Genova","Genova",{"type":47,"coordinates":218},[219,220],11.87211,45.21604,{"lat":220,"lon":219},[223],{"name":224,"role":34,"phone":225,"phoneExt":26,"email":226},"Elisa Benicelli, MD","3470422616","elisa.benicelli@hsanmartino.it",{"facility":228,"status":40,"city":229,"state":26,"zip":230,"country":44,"countryCode":45,"cosmosGeoPoint":231,"geoPoint":235,"contacts":236},"Ospedale A. Manzoni Lecco","Lecco","23900",{"type":47,"coordinates":232},[233,234],9.39704,45.85589,{"lat":234,"lon":233},[237],{"name":238,"role":34,"phone":239,"phoneExt":26,"email":240},"Andrea Salmeggi, MD","3316164800","a.salmeggi@asst-lecco.it",{"facility":242,"status":40,"city":243,"state":26,"zip":244,"country":44,"countryCode":45,"cosmosGeoPoint":245,"geoPoint":249,"contacts":250},"Humanitas Cancer Center","Milan","20089",{"type":47,"coordinates":246},[247,248],12.59836,42.78235,{"lat":248,"lon":247},[251],{"name":252,"role":34,"phone":26,"phoneExt":26,"email":253},"Angelo Dipasquale, MD","angelo.dipasquale@cancercenter.humanitas.it",{"facility":255,"status":40,"city":243,"state":26,"zip":256,"country":44,"countryCode":45,"cosmosGeoPoint":257,"geoPoint":259,"contacts":260},"IRCCS Ospedale Galeazzi Sant'Ambrogio","20157",{"type":47,"coordinates":258},[247,248],{"lat":248,"lon":247},[261],{"name":262,"role":34,"phone":263,"phoneExt":26,"email":264},"Marco Conti Nibali, MD","3335668483","marco.continibali@gmail.com",{"type":266,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100590238","silibinin-in-association-with-concomitant-chemoradiotherapy-and-maintenance-temozolomide-in-stat3-positive-idh-wild-type-newly-diagnosed-glioblastoma-patients-100590238",false,"NCT06964815","Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients","Silibinin in Association With Concomitant Chemoradiotherapy and Maintenance Temozolomide in STAT3 Positive IDH Wild-type, Newly Diagnosed Glioblastoma Patients: a Multicenter, Double-blind, Placebo-controlled, Randomized Study","STRONG","Inclusion Criteria:\n\n* New histologically confirmed diagnosis of glioblastoma (WHO 2021)\n* Local availability of MGMT methylation status\n* Immunohistochemical positivity of activated STAT3 (pSTAT3) expression on the tumor tissue sample. STAT3 expression will be evaluated centrally by UOC Anatomia Patologica of Azienda Ospedale Università di Padova.\n* Chemoradiotherapy start within 7 weeks from surgery\n* Patients without disease progression after surgery\n* Availability of paraffin-embedded tumor tissue\n* Age ≥18 years\n* ECOG PS 0-2; Karnofsky 100-70\n* Signing of informed consent prior to any study procedure\n* Patients (both males and females) should employ adequate contraceptive measures, which should be maintained during the whole duration of the trial (from screening to 6 months after the last dose of Temozolomide).\n* Have adequate bone marrow, liver and kidney function, as measured by the following laboratory assessments conducted within 10 days before the start of study treatment:\n* Hemoglobin \\> 9.0 g\u002Fdl\n* Absolute neutrophil count (ANC) ≥1500\u002Fmm3 without granulocyte colony-stimulating factor (G-CSF) and other hematopoietic growth factors\n* Platelet count ≥100,000\u002Fμl\n* WBC ≥3.0 x 10 9 \u002FL\n* Total bilirubin \\\u003C1.5 times the upper limit of normal\n* ALT and AST \\\u003C3 x the upper limit of normal\n* Serum creatinine \\\u003C1.5 times the upper limit of normal\n* Glomerular filtration rate ≥ 30 mL\u002Fmin\u002F1.73 m2 according to the abbreviated formula Modified Diet in Renal Disease\n* Alkaline phosphatase \\\u003C2.5 x ULN\n* PT-INR\u002FPTT \\\u003C1.5 x upper limit of normal (patients who are therapeutically anticoagulated with anticoagulant drugs will be able to participate provided there is no history of abnormal background in these parameters, based on history).\n* Complete urinalysis\n* Stable and decreasing corticosteroid dosage in the last 10 days before brain MRI\n\nExclusion Criteria:\n\n* Patients diagnosed with glioblastoma (WHO grade IV 2021) who have only had a diagnostic biopsy\n* Chemotherapy, immunotherapy, or antineoplastic therapy for glioblastoma\n* Negative immunohistochemistry of STAT3 expression on the tumor tissue sample\n* Diagnosis of another tumor or secondary brain localization\n* In the investigator's judgment, any evidence of severe or uncontrolled systemic disease including: uncontrolled hypertension; hemorrhagic diathesis; active infection with HBV, HCV, HIV. Screening for such chronic conditions is not required by the protocol; bone marrow reserve or organ dysfunction as demonstrated by laboratory tests.\n* Patients who are unable to comply with study procedures and requirements.\n* Contraindication to Brain MRI\n* Pregnant or breastfeeding patients\n* Patients who are unable to swallow capsules or sachets dissolved in water.\n* Patient unable to sign the Informed Consent\n* Glioblastoma leptomeningeal dissemination\n* Congestive heart failure classified as New York Heart Association (NYHA) Class 2 or higher; Unstable angina (symptoms of angina at rest) or new onset angina ≤3 months prior to screening; myocardial infarction \\\u003C6 months prior to 'start of study treatment; cardiac arrhythmias requiring antiarrhythmic therapy, with the exception of beta-blockers or digoxin; uncontrolled hypertension (systolic blood pressure \\[SBP\\]\\>140 mmHg or diastolic blood pressure \\[DBP\\] \\>90 mmHg) despite optimal medical management.\n* Arterial thrombotic or embolic events such as stroke and\u002For transient ischemic attacks) or\n* Pulmonary embolism in the 6 months prior to the start of study treatment\n* Ongoing infection with grade 2 or higher severity (NCI-CTCAE v 5.0)\n* Known history of human immunodeficiency virus (HIV) infection; hepatitis B or C active or chronic requiring treatment with antiviral therapy\n* History of organ allotransplantation\n* Evidence or history of any bleeding diathesis (including mild hemophilia), regardless of its severity;\n* Injuries, ulcers or bone fractures that have not fully resolved.\n* Renal failure requiring hemodialysis or peritoneal dialysis\n* Presenting interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained.\n* Persistent proteinuria \\>3.5 g\u002F24 hours as measured by urinary protein-creatinine ratio from a urine sample (≥ Grade 3, NCI-CTCAE v 5.0). CTCAE 5.0 is also available in Appendix 1.","ALL","18 Years","99 Years",{"count":279,"type":280},110,"ESTIMATED","INTERVENTIONAL",[283],"NA","Multicenter, double-blind, placebo-controlled, randomized trial.\n\nPatients affected by STAT3 positive newly diagnosed glioblastoma will be eligible. Patients are randomized using a stratified block randomization method with a 1:1 ratio in two arms:\n\n• Experimental\u002FControl arm: Concomitant radiotherapy (60 gy in 30 fractions) + temozolomide 75mg\u002Fmq + silibinin\u002Fplacebo 2 sachets\u002Fday dissolved in water throughout concomitant treatment followed by temozolomide cp, 150 mg\u002Fm2-200mg\u002Fm2, g1-5 q28d + silibinin\u002Fplacebo 2 sachets\u002Fday dissolved in water, day 1-28, q28d for 6-12 cycles. Silibinin\u002FPlacebo may be continued until disease progression at the discretion of the physician.\n\nPatients will be stratified based on:\n\n* Type of surgery (complete Vs partial)\n* MGMT methylation status (methylated Vs non-methylated)\n* ECOG PS (0-1 Vs 2)",[286,287],"Glioblastoma","IDH Wild-type and STAT3-positive Glioblastoma",[286,289,290,291,292],"IDH wild-type and STAT3-positive glioblastoma","silibinin","temozolomide","placebo","2025-12-01",{"date":295,"type":296},"2025-12-02","ACTUAL",{"date":298,"type":296},"2025-11-12",{"date":300,"type":280},"2027-10",{"name":5,"class":6},16]